Stockscreener 앱 받기
18.51
0.05%
0.01
시간 외 거래:
18.30
-0.21
-1.13%
전일 마감가:
$18.50
열려 있는:
$19.26
하루 거래량:
2.18M
Relative Volume:
1.08
시가총액:
$2.63B
수익:
-
순이익/손실:
$-45.61M
주가수익비율:
-57.22
EPS:
-0.3235
순현금흐름:
$-45.40M
1주 성능:
+1.42%
1개월 성능:
-5.08%
6개월 성능:
+61.52%
1년 성능:
+153.56%
1일 변동 폭
$17.90
$19.26
1주일 범위
$17.45
$19.30
52주 변동 폭
$6.55
$20.22
트레비 테라퓨틱스 Stock (TRVI) Company Profile
명칭
Trevi Therapeutics Inc
전화
203-304-2499
주소
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
18.51 | 2.57B | 0 | -45.61M | -45.40M | -0.3235 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-08-21 | 개시 | Morgan Stanley | Overweight |
| 2025-07-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-03-10 | 재확인 | Needham | Buy |
| 2025-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-30 | 개시 | Raymond James | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-12 | 개시 | B. Riley Securities | Buy |
| 2022-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | BMO Capital Markets | Outperform |
| 2019-06-03 | 개시 | Needham | Buy |
| 2019-06-03 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | Stifel | Buy |
모두보기
트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스
Trevi Therapeutics to present at August biotech conferences on its chronic cough therapy Haduvio™ - Pluang
Trevi Therapeutics to Participate in Upcoming August Conferences - Yahoo Finance
Trevi Therapeutics, Inc. Revenue Breakdown – NASDAQ:TRVI - TradingView
Trevi Therapeutics, Inc. $TRVI Shares Sold by Orbimed Advisors LLC - MarketBeat
Octagon Capital Advisors LP Reduces Stock Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Inc (TRVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Trevi Therapeutics Inc (TRVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Trevi Therapeutics Inc (TRVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Trevi Therapeutics Inc (TRVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Trevi Therapeutics Inc (TRVI) Institutional Confidence - TradingKey
Trevi Therapeutics Inc (TRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
TRVI|Trevi Therapeutics Inc|Price:17.535|Chg%:+0.355 - TradingKey
Trevi Therapeutics Inc|Price:17.535|Chg%:+0.355 - TradingKey
Affinity Asset Advisors LLC Sells 150,000 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Siren L.L.C. Cuts Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Fifth Third Bancorp Invests $1.53 Million in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Serina Therapeutics Appoints Farrell Simon to its Board of Directors - The Manila Times
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
BMO Capital Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Trevi Therapeutics (NASDAQ:TRVI) Rating Increased to Strong-Buy at BMO Capital Markets - MarketBeat
TRVI Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $24 - Moomoo
BMO Capital Initiates Trevi Therapeutics at Outperform With $36 Price Target - marketscreener.com
Trevi Therapeutics Initiated at Outperform by BMO Capital - Moomoo
BMO Capital Initiates Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $36 - Moomoo
BMO initiates Trevi Therapeutics stock at Outperform, $36 target By Investing.com - Investing.com Canada
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 5.1%Here's Why - MarketBeat
TRVI Maintains Buy by B. Riley Securities -- Price Target Raised to $31.00 - GuruFocus
B. Riley Financial Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - MarketBeat
TRVI Maintains Buy Rating -- Price Target Raised to $24.00 by HC Wainwright - GuruFocus
B. Riley Adjusts Trevi Therapeutics Price Target to $31 From $21, Maintains Buy Rating - marketscreener.com
HC Wainwright Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - MarketBeat
Trevi Therapeutics Announces Proposed Public Offering of Common Stock - GuruFocus
Trevi Therapeutics stock price target raised to $24 by H.C. Wainwright - Investing.com
Trevi Therapeutics (TRVI) Is Up 6.9% After Haduvio Cough Data And New ILD Trial PlanHas The Bull Case Changed? - webull.com
TRVI Surges As Trevi Therapeutics Draws Fresh Bullish Momentum - timothysykes.com
TRVI Surges As Trevi Therapeutics Draws Aggressive Buyers - timothysykes.com
TRVI Jumps As Trevi Therapeutics Extends Rally On Heavy Interest - StocksToTrade
Trevi Therapeutics Stock Jumps As Momentum Traders Pile In - timothysykes.com
TRVI Jumps As Trevi Therapeutics Extends Bullish Run - timothysykes.com
symbol__ Stock Quote Price and Forecast - CNN
Trevi Therapeutics (NASDAQ:TRVI) Hits New 1-Year HighHere's Why - MarketBeat
Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market - Yahoo Finance
Why Trevi Therapeutics (TRVI) Stock Is Up Today - Moomoo
Trevi climbs as GSK drops chronic cough therapy (TRVI:NASDAQ) - Seeking Alpha
TRVI Stock Firms Up As Haduvio Story Hits Center Stage - StocksToTrade
Trevi Therapeutics (TRVI) Sees Significant Price Increase - GuruFocus
Trevi Therapeutics (NASDAQ:TRVI) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23 - Moomoo
트레비 테라퓨틱스 (TRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.84%
0.86%
자본화:
|
볼륨(24시간):